论文部分内容阅读
目的:观察拉米夫定治疗乙型肝炎肝硬化失代偿期患者的疗效。方法:将42例失代偿期肝硬化随机分为两组,治疗组22例,对照组20例。两组均采用常规内科综合治疗,治疗组加用拉米夫定100 mg/d口服,疗程1 a。结果:治疗组1 a治疗结束时肝功能恢复情况及HBV-DNA转阴率均优于对照组(P<0.05)。治疗组病死率9.1%,对照组为20.0%。结论:拉米夫定治疗失代偿期乙肝肝硬化能明显改善患者的肝功能及预后。
Objective: To observe the efficacy of lamivudine in the treatment of patients with decompensated hepatitis B cirrhosis. Methods: Forty-two patients with decompensated cirrhosis were randomly divided into two groups: treatment group (n = 22) and control group (n = 20). Both groups were treated by conventional internal medicine. The treatment group was treated with lamivudine 100 mg / d orally for 1 year. Results: The recovery of liver function and the negative rate of HBV-DNA in the treatment group were better than those in the control group (P <0.05). The case fatality rate was 9.1% in the treatment group and 20.0% in the control group. Conclusion: Lamivudine treatment of decompensated hepatitis B cirrhosis patients can significantly improve liver function and prognosis.